FDA approves first drug to reduce excessive sweating

The first drug, Qbrexza, against excessive sweating has been approved by the Food and Drug Administration. As reported by the company, according to trials carried out, 53% of the patient under Qbrexza treatment indicated a reduced sweat production by roughly half followed by 28% in a comparison group using non-medicated cloth.

Link: https://docs.google.com/spreadsheets/d/1kHqZ1OxmmGFJ_jd_GFN7l8B_1Iw8j1-X8xbEQIk_XDk/edit#gid=975067149